leisure time -WSS

leisure time

author：leisure time 2025-09-30 11:57:45 - browse：812

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： FDA advisers back CAR

entertainment

WSS

Researchers tackle phage therapy hurdles for wider adoption

Amid AI frenzy, a top HHS official's quest to create safeguards

EPA limits use of carcinogenic gas for sterilizing medical devices

Steward Health Care Massachusetts hospitals face fiscal disaster

How to save health care price transparency rules

Reporting on presidential health from Reagan to Trump and Biden

hotspot

leisure time

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: CAR

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Heart attack and stroke risk calculators need revising

A new drug could help frostbite victims avoid its ravages

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Wikipedia

How many hemophilia patients actually want gene therapy?

Opioid cravings were reduced by anti

Obamacare plans could cover weight loss drugs

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Boston's new lab space is opening empty

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

entertainment

leisure time

entertainment

focus